Skip to main content
CMS.gov Centers for Medicare & Medicaid Services CMS.gov Centers for Medicare & Medicaid Services opens in new window
CMS.gov Centers for Medicare & Medicaid Services
Centers for Medicare & Medicaid Services

Main header

  • About Us
  • Newsroom
  • Data & Research
Newsroom

Newsroom_Navigation

  • Press Kit
  • Data
  • Contact
  • Blog
  • Podcast

 

 

 

Press release

CMS unleashes innovation to ensure our nation’s seniors have access to the latest advancements

Jan 12, 2021
  • Coverage
  • Initiatives

Share

opens in new window opens in new window opens in new window

Today, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that propels innovative technology so Medicare beneficiaries have access to the latest, most advanced devices. Today’s action represents a  step forward that will help smooth the Medicare coverage pathway for innovative products, resulting in faster access to new devices for America’s seniors. This action delivers on CMS’s Unleashing Innovation and Patients Over Paperwork Initiative.

The Medicare Coverage of Innovative Technology (MCIT) (CMS-3372-F) final rule will provide the nation’s more than 60 million Medicare beneficiaries access to the latest medical technology faster than ever. Under current rules, FDA approval of a device is followed by an often lengthy and costly process for Medicare coverage. The lag time between the two results in innovators first spending time and resources on FDA approval, and then subsequently on the Medicare coverage process. This causes undue burden for innovators and could delay access to these potentially lifesaving technologies during the existing Medicare coverage determination process.

“Government processes have slowed beneficiaries’ access to innovative treatments. Despite being deemed safe and effective by the FDA, Medicare beneficiaries have not had predictable, immediate access to innovative breakthrough devices,” said CMS Administrator Seema Verma. “In an ever-evolving health care marketplace, CMS remains committed to transforming the health care delivery system through initiatives like MCIT that focus on results, removing government barriers to advancing innovations, fostering competition, and ensuring quicker access to the most advanced therapies for Medicare beneficiaries while providing them with better value and outcomes.”

The MCIT rule will eliminate this lag time for both seniors and innovators. It will create a new, accelerated Medicare coverage pathway for innovative products that the FDA deems “breakthrough,” which FDA approves on an expedited basis and could include devices harnessing new technologies like implants or gene-based tests to diagnose or treat life-threatening or irreversibly debilitating diseases or conditions like cancer and heart disease. Under the MCIT rule, Medicare can provide national coverage simultaneously with FDA approval, up to a period of four years.  After the coverage period is over, CMS will reevaluate the device based on clinical and real-world evidence of improvement in health outcomes among Medicare beneficiaries to determine more permanent coverage. This four-year timeline may incentivize the manufacturers of these breakthrough devices to develop additional evidence regarding the applicability of their products to the Medicare population, so they might continue Medicare coverage beyond the initial four years.

Importantly, because the MCIT rule will provide national Medicare coverage for four years, it will harmonize with the local coverage determination (LCD) process, thus promoting equal access for seniors regardless of where they live.  Currently, under the local coverage process, 16 Medicare Administrative Contractors (MACs) make Medicare coverage decisions on the local level – 12 for Medicare Parts A and B, and four for Durable Medical Equipment. MACs can cover items or services on a claim-by-claim basis or through a Local Coverage Determination (LCD), which applies only to that MAC’s jurisdiction. In the absence of national Medicare coverage decision for an innovative technology, the technology could be covered in one area of the country but not in another.

Additionally, to secure an LCD, innovators are required to seek separate decisions from each of the MACs.  MCIT makes this step for innovators unnecessary, which helps innovators and beneficiaries alike. Under MCIT, breakthrough devices are given national coverage for four years, as early as the date of FDA approval, meaning innovators no longer have to seek LCDs from each MAC.  Innovators will have the option to choose when they would like coverage to begin.  This will give innovators flexibility to align the coverage process with their manufacturing and distribution cycles.

After the final rule takes effect, upon manufacturer request, Medicare may cover through MCIT eligible breakthrough devices the FDA has approved, including breakthrough devices that received FDA marketing authorization approval within two calendar years prior to the final rule’s effective date, giving Medicare beneficiaries access to these innovative and potentially life-saving devices.

In addition, the MCIT final rule will clarify the standard CMS uses to determine whether Medicare should cover items and services, like devices and surgical procedures. Under the Medicare law, with relatively few exceptions, the program can only cover items or services that are “reasonable and necessary” for the diagnosis or treatment of illness or injury or improve the functioning of a malformed body member. This final rule will codify CMS’s definition of reasonable and necessary in regulation to give innovators a clearer understanding of CMS standards. 

Based on public comment, the final rule included a more flexible start date for MCIT coverage.  Manufacturers can choose the date coverage begins to better align with market availability.  Also, as stakeholders requested, CMS will gather more information about utilizing commercial insurer coverage policies and utilize them under specific circumstances.

For a fact sheet on the final rule (CMS-3372-F), please visit: https://www.cms.gov/newsroom/fact-sheets/medicare-coverage-innovative-technology-cms-3372-f

The final rule (CMS-3372-F) can be downloaded from the Federal Register at: https://www.federalregister.gov/public-inspection/2021-00707/medicare-program-medicare-coverage-of-innovative-technology-and-definition-of-reasonable-and

 

###
Get CMS news at cms.gov/newsroom, sign up for CMS news via email and follow CMS on @CMSgov.

  • Previous
  • Next

Related Releases

  • Medicare Coverage of Innovative Technology (CMS-3372-F)
    Jan 12, 2021
  • CMS Proposes Updates to Coverage Policy for Autologous Blood-Derived Products for Chronic Non-Healing Wounds
    Dec 21, 2020
  • CMS Updates Coverage Policies for Artificial Hearts and Ventricular Assist Devices (VADs)
    Dec 01, 2020
  • Organ Procurement Organization (OPO) Conditions for Coverage Final Rule: Revisions to Outcome Measures for OPOs CMS-3380-F
    Nov 20, 2020
  • CMS Finalizes Policy that will Increase the Number of Available Lifesavings Organs by Holding Organ Procurement Organizations Accountable through Transparency and Competition
    Nov 20, 2020

Contact us

CMS News and Media Group
Catherine Howden, Director
Brian Leshak, Deputy Director
Jason Tross, Deputy Director

Media Inquiries Form
202-690-6145

Get email updates

Sign up to get the latest information about your choice of CMS topics in your inbox. Also, you can decide how often you want to get updates.

CMS & HHS WEBSITES

  • Medicare.govopens in new window
  • MyMedicare.govopens in new window
  • Medicaid.govopens in new window
  • InsureKidsNow.govopens in new window
  • HealthCare.govopens in new window
  • HHS.govopens in new window

HELPFUL LINKS

  • Acronyms
  • Archive
  • Contacts
  • Glossary
  • Privacy policy
  • Privacy settings

RSS FEEDS

  • Newsroom
  • Blog
  • Podcast
U.S. Department of Health & Human Servicesopens in new window Centers for Medicare & Medicaid Servicesopens in new window

A federal government website managed and paid for by the U.S. Centers for Medicare & Medicaid Services.

7500 Security Boulevard, Baltimore, MD 21244

opens in new window opens in new window opens in new window

TOOLS

  • Web policiesopens in new window
  • Plain languageopens in new window
  • No Fear Actopens in new window
  • Freedom of Information Actopens in new window
  • Inspector Generalopens in new window